BridgeBio Pharma BBIO Estimated fair value of deferred royalty obligation under funding agreement, net embedded derivative liability
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:DeferredRoyaltyObligationUnderFundingAgreementNetOfEmbeddedDerivativeLiabilityFairValueDisclosure.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's estimated fair value of deferred royalty obligation under funding agreement, net embedded derivative liability.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's estimated fair value of deferred royalty obligation under funding agreement, net embedded derivative liability?
- BridgeBio Pharma (BBIO) reported estimated fair value of deferred royalty obligation under funding agreement, net embedded derivative liability of $554.7M in Q1 2026.